Academic Highlights: Alzheimer's Disease: Translating Neurochemical Insights Into Clinical Benefits
J Clin Psychiatry 2000;61(10):791-802
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Click to enlarge page
Dr. Changiz Geula reviewed recent evidence that updates the “cholinergic hypothesis” and provides insights into the clinical efficacy of cholinesterase (ChE) inhibitors. Alzheimer’s disease is widely acknowledged to involve characteristic morphologic brain lesions and neurochemical changes particularly within cortical cholinergic systems. Pathologic lesions in the brains of Alzheimer’s disease patients at postmortem consist of extracellular plaques formed primarily of the amyloid-protein and intraneuronal neurofibrillary tangles, stated Dr. Geula.